Enhanced expression of interferon-γ-induced antigen-processing machinery components in a spontaneously occurring cancer

Neoplasia

Volumn 9, Issue 11, 2007, Pages 960-969

  Cerruti, Fulvia ^a   Martano, Marina ^a   Petterino, Claudio ^b   Bollo, Enrico ^a   Morello, Emanuela ^a   Bruno, Renato ^a   Buracco, Paolo ^a   Cascio, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antigen processing; Immunoproteasome; MHC class I epitopes; PA28; Proteasome

Indexed keywords

CYTOSOL AMINOPEPTIDASE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMMUNOPROTEASOME; IMMUNOPROTEASOME PA28; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CARCINOGENESIS; CAT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME SUBUNIT; FEMALE; FIBROSARCOMA; GENE EXPRESSION REGULATION; MALE; MOLECULAR RECOGNITION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; T LYMPHOCYTE ACTIVATION;

EID: 36049051956     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07649     Document Type: Article

References (48)

1. Goldberg AL, Cascio P, Saric T, and Rock KL (2002). The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39, 147-164.
2. Anderton SM and Wraith DC (2002). Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol 2, 487-498.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, and Schreiber RD (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998.
4. Khong HT and Restifo NP (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3, 999-1005.
5. Voges D, Zwickl P, and Baumeister W (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68, 1015-1068.
6. Hershko A and Ciechanover A (1998). The ubiquitin system. Annu Rev Biochem 67, 425-479.
7. Rechsteiner M, Realini C, and Ustrell V (2000). The proteasome activator 11S REG (PA28) and class I antigen presentation. Biochem J 345, 1-15.
8. Harris CA, Hunte B, Krauss MR, Taylor A, and Epstein LB (1992). Induction of leucine aminopeptidase by interferon-gamma. Identification by protein microsequencing after purification by preparative two-dimensional gel electrophoresis. J Biol Chem 267, 6865-6869.
9. Beninga J, Rock KL, and Goldberg AL (1998). Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem 273, 18734-18742.
10. Mo XY, Cascio P, Lemerise K, Goldberg AL, and Rock KL (1999). Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J Immunol 163, 5851-5859.
11. Reits E, Griekspoor A, Neijssen J, Groothuis T, Jalink K, van Veelen P, Janssen H, Calafat J, Drijfhout JW, and Neefjes J (2003). Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18, 97-108.
12. Saric T, Graef CI, and Goldberg AL (2004). Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 279, 46723-46732.
13. Cascio P, Hilton C, Kisselev AF, Rock KL, and Goldberg AL (2001). 26S Proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 20, 2357-2366.
14. Rock KL, York IA, and Goldberg AL (2004). Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5, 670-677.
15. Cascio P, Call M, Petre BM, Walz T, and Goldberg AL (2002). Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J 21, 2636-2645.
16. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, et al. (2000). Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12, 107-117.
17. Van den Eynde BJ and Morel S (2001). Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 13, 147-153.
18. Chapiro J, Claverol S, Piette F, Ma W, Stroobant V, Guillaume B, Gairin JE, Morel S, Burlet-Schiltz O, Monsarrat B, et al. (2006). Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol 176, 1053-1061.
19. Chang CC and Ferrone S (2007). Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56, 227-236.
20. Seliger B, Maeurer MJ, and Ferrone S (2000). Antigen-processing machinery breakdown and tumor growth. Immunol Today 21, 455-464.
21. Seliger B, Wollscheid U, Momburg F, Blankenstein T, and Huber C (2000). Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56, 327-336.
22. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, and Seliger B (2001). Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19, 1211-1220.
23. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, and Storkel S (2003). Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 9, 1721-1727.
24. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Storkel S, and Seliger B (2004). MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 109, 265-273.
25. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, and Seliger B (2004). HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64, 215-220.
26. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, and Seliger B (2005). Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11, 2552-2560.
27. Hendrick MJ, Goldschmidt MH, Shofer FS, Wang YY, and Somlyo AP (1992). Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 52, 5391-5394.
28. Goldschmidt MH and Henrick MJ (2002). Tumors of the skin and soft tissues. In Meuten, DJ (Ed.), Tumors in Domestic Animals, 4th ed, Iowa State Press, Ames, IA, USA pp. 85-86.
29. Vail DM and MacEwen EG (2000). Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18, 781-792.
30. McNiel EA (2001). Vaccine-associated sarcomas in cats: a unique cancer model. Clin Orthop Relat Res 382, 21-27.
31. Owen L (1980). TNM Classification of Tumors in Domestic Animals World Health Organization, Geneva.
32. Ferrone S, Finerty JF, Jaffee EM, and Nabel GJ (2000). How much longer will tumour cells fool the immune system? Immunol Today 21, 70-72.
33. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, and Stern PL (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18, 89-95.
34. Marincola FM, Jaffee EM, Hicklin DJ, and Ferrone S (2000). Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74, 181-273.
35. Groettrup M, Standera S, Stohwasser R, and Kloetzel PM (1997). The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA 94, 8970-8975.
36. Nandi D, Woodward E, Ginsburg DB, and Monaco JJ (1997). Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor beta subunits. EMBO J 16, 5363-5375.
37. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, and Colbert RA (1998). Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187, 97-104.
38. Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, and Ting JP (1997). Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 6, 591-600.
39. Zheng P, Guo Y, Niu Q, Levy DE, Dyck JA, Lu S, Sheiman LA, and Liu Y (1998). Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396, 373-376.
40. Macy DW and Hendrick MJ (1996). The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract 26, 103-109.
41. Akiyama K, Yokota K, Kagawa S, Shimbara N, Tamura T, Akioka H, Nothwang HG, Noda C, Tanaka K, and Ichihara A (1994). cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science 265, 1231-1234.
42. Stohwasser R, Standera S, Peters I, Kloetzel PM, and Groettrup M (1997). Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits. Eur J Immunol 27, 1182-1187.
43. Singh S, Awasthi N, Egwuagu CE, and Wagner BJ (2002). Immunoproteasome expression in a nonimmune tissue, the ocular lens. Arch Biochem Biophys 405, 147-153.
44. Gaczynska M, Rock KL, Spies T, and Goldberg AL (1994). Peptidase activities of proteasomes are differentially regulated by the MHC-encoded genes LMP2 and LMP7. Proc Natl Acad Sci USA 91, 9212-9217.
45. Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, and Groettrup M (1999). Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 29, 4037-4042.
46. Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, and Rock KL (2005). Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. J Immunol 175, 6605-6614.
47. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, and Coltman C (1990). Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 82, 1071.
48. Kowalzick L, Weyer U, Lange P, and Breitbart EW (1990). Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma. Dermatologica 181, 298-303.